LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

(2019) Kornelia Kotseva et al.   European Journal of Preventive Cardiology

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

(2019) Jane Armitage et al.   LANCET

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses

(2019) Fadia Tohme Shaya et al.   American Journal of Cardiovascular Drugs

Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study

(2019) Jens Sundbøll et al.   THROMBOSIS RESEARCH

El informe analítico ideal del perfil lipídico. Necesidad de un consenso

(2018) Juan Pedro-Botet et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3

(2017) Yu-Hsuan Lin et al.   Oncotarget

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients

(2016) Anselm K. Gitt et al.   ATHEROSCLEROSIS

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

(2016) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60

(2016) Lluis Masana et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients

(2015) Olivier Descamps et al.   ATHEROSCLEROSIS

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

(2013) Alberico Catapano et al.   Clinical Lipidology

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

(2012) Doralisa Morrone et al.   ATHEROSCLEROSIS

Obesity and Dyslipidemia

(2011) Remco Franssen et al.   MEDICAL CLINICS OF NORTH AMERICA

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

A systematic review and meta-analysis on the therapeutic equivalence of statins

(2009) T.-C. Weng et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

(2008) Thomas M. van Himbergen et al.   JOURNAL OF LIPID RESEARCH